Key takeaways
- Readiness is about what a company is doing, not who they are. Whether they grew headcount last quarter, not how many people they employ.
- Two companies with the same size and funding can be in very different buying positions: one just raised a round, the other's been quiet for a year.
- The best window is right after something changes, before that budget's committed elsewhere.
Readiness scoring rates how likely an account is to be in a buying window right now, based on what it is actually doing (funding, hiring, clinical trial activity, regulatory milestones) rather than who it is on paper. It is Arcova's term for turning that read into a comparable score instead of a gut feel.
What readiness measures
Readiness is about one thing: given what has happened at an account lately, is now a good moment to reach out? That is a different question from whether the account is a good customer in general. A company can be an excellent long-term fit and have no readiness at all right now, because nothing has changed to give you a reason to talk.
It is about what a company is doing, not who they are: whether they grew headcount last quarter, not how many people they employ. The inputs are events, a funding round closing, a clinical operations leader being hired, a trial moving into the next phase, an FDA designation, a company confirmed for an upcoming conference, and every event has a date, so it counts for more when it is fresh and fades as it ages.
Readiness scoring vs. a fit score
A fit score measures how closely an account and buyer match an ideal customer profile, using relatively stable attributes: therapeutic area, modality, development stage, company size, buyer function and seniority. It tells you whether an account is in a company's addressable market at all. It does not change from week to week, and it says nothing about timing.
Readiness is the second, separate layer: within the accounts that already clear fit, which ones have something recent happening that makes outreach more likely to land now, rather than in three months or a year? Most teams check fit first, then rank the good-fit accounts by readiness, because the two are different questions and neither one alone is enough. A high-fit, low-readiness account is worth monitoring; a high-fit, high-readiness account is worth calling this week.
Why timing matters this much in life science sales
In most life science categories, budget and mandate are not steady-state; they show up in bursts, tied to discrete, dated events. A biotech has no real budget for outside clinical operations support until it files an IND or moves into the next trial phase. A CDMO conversation does not start until a sponsor's formulation work reaches the point where it actually needs scale-up capacity. A tools or services vendor's best window is often the weeks right after a funding close, before that budget gets allocated elsewhere.
Static firmographic fit cannot see any of that. Two companies can look identical on a firmographic profile, same modality, same size, same therapeutic area, and be in completely different buying states because one just raised a Series B and the other has not moved in eighteen months. Readiness scoring exists specifically to surface that difference, using the same kind of public, industry-specific events that make life science buying cycles observable in the first place. See signal-based GTM for life science for the broader framing this sits inside.
Turning all of that into a single, comparable score per account is a method in itself. For the step-by-step version, see how to score readiness.